NBIX Quote, Financials, Valuation and Earnings

Armata Pharmaceuticals has a net margin of 1.38% compared to Neurocrine Biosciences's net margin of --. Neurocrine Biosciences's return on equity of 12% beat Armata Pharmaceuticals's return on equity of --.

Neurocrine Biosciences has a consensus price target of $162.19, signalling upside risk potential of 21.51%. On the other hand Armata Pharmaceuticals has an analysts' consensus of $9.00 which suggests that it could grow by 281.36%. Given that Armata Pharmaceuticals has higher upside potential than Neurocrine Biosciences, analysts believe Armata Pharmaceuticals is more attractive than Neurocrine Biosciences.

Neurocrine Biosciences has a beta of 0.243, which suggesting that the stock is 75.74% less volatile than S&P 500. In comparison Armata Pharmaceuticals has a beta of 0.938, suggesting its less volatile than the S&P 500 by 6.224%.

Neurocrine Biosciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Armata Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Neurocrine Biosciences pays -- of its earnings as a dividend. Armata Pharmaceuticals pays out -- of its earnings as a dividend.

Neurocrine Biosciences quarterly revenues are $572.6M, which are larger than Armata Pharmaceuticals quarterly revenues of --. Neurocrine Biosciences's net income of $7.9M is higher than Armata Pharmaceuticals's net income of -$6.5M. Notably, Neurocrine Biosciences's price-to-earnings ratio is 45.25x while Armata Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Neurocrine Biosciences is 5.72x versus 1,000.03x for Armata Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Capricor Therapeutics has a net margin of 1.38% compared to Neurocrine Biosciences's net margin of -63.94%. Neurocrine Biosciences's return on equity of 12% beat Capricor Therapeutics's return on equity of -75.99%.

Neurocrine Biosciences has a consensus price target of $162.19, signalling upside risk potential of 21.51%. On the other hand Capricor Therapeutics has an analysts' consensus of $20.60 which suggests that it could grow by 184.53%. Given that Capricor Therapeutics has higher upside potential than Neurocrine Biosciences, analysts believe Capricor Therapeutics is more attractive than Neurocrine Biosciences.

Neurocrine Biosciences has a beta of 0.243, which suggesting that the stock is 75.74% less volatile than S&P 500. In comparison Capricor Therapeutics has a beta of 0.820, suggesting its less volatile than the S&P 500 by 18.02%.

Neurocrine Biosciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Capricor Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Neurocrine Biosciences pays -- of its earnings as a dividend. Capricor Therapeutics pays out -- of its earnings as a dividend.

Neurocrine Biosciences quarterly revenues are $572.6M, which are larger than Capricor Therapeutics quarterly revenues of $11.1M. Neurocrine Biosciences's net income of $7.9M is higher than Capricor Therapeutics's net income of -$24.4M. Notably, Neurocrine Biosciences's price-to-earnings ratio is 45.25x while Capricor Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Neurocrine Biosciences is 5.72x versus 12.59x for Capricor Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Perspective Therapeutics has a net margin of 1.38% compared to Neurocrine Biosciences's net margin of --. Neurocrine Biosciences's return on equity of 12% beat Perspective Therapeutics's return on equity of --.

Neurocrine Biosciences has a consensus price target of $162.19, signalling upside risk potential of 21.51%. On the other hand Perspective Therapeutics has an analysts' consensus of $14.1071 which suggests that it could grow by 245.76%. Given that Perspective Therapeutics has higher upside potential than Neurocrine Biosciences, analysts believe Perspective Therapeutics is more attractive than Neurocrine Biosciences.

Neurocrine Biosciences has a beta of 0.243, which suggesting that the stock is 75.74% less volatile than S&P 500. In comparison Perspective Therapeutics has a beta of 1.177, suggesting its more volatile than the S&P 500 by 17.701%.

Neurocrine Biosciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Neurocrine Biosciences pays -- of its earnings as a dividend. Perspective Therapeutics pays out -- of its earnings as a dividend.

Neurocrine Biosciences quarterly revenues are $572.6M, which are larger than Perspective Therapeutics quarterly revenues of --. Neurocrine Biosciences's net income of $7.9M is higher than Perspective Therapeutics's net income of -$18.2M. Notably, Neurocrine Biosciences's price-to-earnings ratio is 45.25x while Perspective Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Neurocrine Biosciences is 5.72x versus 28.76x for Perspective Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Protalix BioTherapeutics has a net margin of 1.38% compared to Neurocrine Biosciences's net margin of -35.79%. Neurocrine Biosciences's return on equity of 12% beat Protalix BioTherapeutics's return on equity of 10.9%.

Neurocrine Biosciences has a consensus price target of $162.19, signalling upside risk potential of 21.51%. On the other hand Protalix BioTherapeutics has an analysts' consensus of $14.00 which suggests that it could grow by 879.02%. Given that Protalix BioTherapeutics has higher upside potential than Neurocrine Biosciences, analysts believe Protalix BioTherapeutics is more attractive than Neurocrine Biosciences.

Neurocrine Biosciences has a beta of 0.243, which suggesting that the stock is 75.74% less volatile than S&P 500. In comparison Protalix BioTherapeutics has a beta of -0.227, suggesting its less volatile than the S&P 500 by 122.694%.

Neurocrine Biosciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Protalix BioTherapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Neurocrine Biosciences pays -- of its earnings as a dividend. Protalix BioTherapeutics pays out -- of its earnings as a dividend.

Neurocrine Biosciences quarterly revenues are $572.6M, which are larger than Protalix BioTherapeutics quarterly revenues of $10.1M. Neurocrine Biosciences's net income of $7.9M is higher than Protalix BioTherapeutics's net income of -$3.6M. Notably, Neurocrine Biosciences's price-to-earnings ratio is 45.25x while Protalix BioTherapeutics's PE ratio is 35.75x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Neurocrine Biosciences is 5.72x versus 2.01x for Protalix BioTherapeutics. Usually stocks with elevated PS ratios are considered overvalued.